varilrix hsa-free varicella vaccine live attenuated 0.5ml powder for injection vial
glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.
varilrix hsa-free varicella vaccine live attenuated 0.5ml injection vial plus diluent ampoule composite pack
glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.
varilrix hsa-free varicella vaccine live attenuated 0.5ml injection vial plus diluent syringe composite pack
glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immuncompromised patients with no history of the disease.
imojev japanese encephalitis vaccine (live, attenuated) powder for injection vial plus diluent vial
biocelect pty ltd - japanese encephalitis virus, quantity: 4 pfu - injection, powder for - excipient ingredients: albumin; mannitol; glutamic acid; histidine; sodium chloride; potassium hydroxide; lactose monohydrate; water for injections - imojev is indicated for prophylaxis of japanese encephalitis caused by the japanese encephalitis virus, in individuals from 9 months of age and over.
rotarix human rotavirus (live attenuated oral vaccine) oral liquid
glaxosmithkline australia pty ltd - rotavirus, quantity: 1000000 ccid50/dose - oral liquid, suspension - excipient ingredients: sucrose; water for injections; adipic acid; sodium hydroxide; glucose monohydrate; sodium chloride; potassium chloride; magnesium sulfate heptahydrate; ferric nitrate nonahydrate; dibasic sodium phosphate dihydrate; sodium pyruvate; folic acid; calcium pantothenate; inositol; choline chloride; nicotinamide; pyridoxine hydrochloride; thiamine hydrochloride; riboflavine; cystine; tyrosine; arginine; glycine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine; threonine; tryptophan; serine; valine; glutamine; calcium chloride dihydrate; sodium bicarbonate - rotarix is indicated for the prevention of rotavirus gastroenteritis. see section 5.1 pharmacodynamic properties - clinical trials.
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.
varilrix varicella vaccine live attenuated 0.5ml injection vial plus diluent ampoule composite pack
glaxosmithkline australia pty ltd - live varicella vaccine -
varilrix varicella vaccine live attenuated 0.5ml injection vial plus diluent syringe composite pack
glaxosmithkline australia pty ltd - live varicella vaccine -
chicken anaemia virus living, attenuated strain 26p4
intervet australia pty limited - chicken anaemia virus (living, attenuated) strain 26p4 - unknown - chicken anaemia virus (living, attenuated) strain 26p4 vaccine-viral active 0.0 - active constituent
varivax powder and solvent for suspension for injection in pre-filled syringe
merck sharp & dohme b.v. waarderweg 39, haarlem noord-holland, 2031 bn, netherlands - varicella virus, oka, merck strain, live, attenuated - powder and solvent for suspension for injection - varicella virus oka/merck strain (live, attenuated) - vaccines